72 / 74 · 0:51 · Original AXON film
EloraTZP
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
EloraTZP | Combination research
EloraTZP is Lilly's research name for combining eloralintide with tirzepatide. It describes a combination program rather than a new single peptide molecule. [1]
SPONSOR REPORT | Phase 2b
In September 2026, Lilly reported a forty-eight-week phase 2b study involving 367 adults with overweight or obesity and type 2 diabetes. [1]
Reported outcomes and tolerability
The company reported larger numerical weight and A1C reductions with three of the four combinations than with tirzepatide alone. Gastrointestinal events occurred more frequently in the combination groups. [1]
Combination evidence is product-specific
These are sponsor-reported results that need full methodological scrutiny. They do not validate independently mixed products, and the tested population limits broader conclusions. [1]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Lilly (30 September 2026): EloraTZP phase 2b results in adults with obesity or overweight and type 2 diabetes →Combination identity; 367 participants; 48-week study; reported comparative outcomes and gastrointestinal tolerability.
